NXTS
Nexentis Technologies Inc.
$5.08
-4.87%
$3.7M
No data for this timeframe.
Vol
Market Cap$3.7M
Cap SizeNano Cap
Insider Activity0B / 1S
Insider Net $-$172.09
SEC Reports4
Recent Activity
Jun 17, 2026
other
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Ne
Jun 15, 2026
SEC
Nexentis Technologies is offering 311,876 shares at $4.008/share (20% discount to $5.01 last sale), raising ~$1.25M befo
424B5 — Impact 6/10
Jun 12, 2026
SEC
Nexentis Technologies Inc. entered into a securities purchase agreement to sell 311,876 shares of common stock in a regi
8-K — Impact 6/10
Apr 6, 2026
SEC
Nexentis Technologies Inc. (NXTS) is executing a 1-for-7 reverse stock split, reducing the number of outstanding shares
8-K — Impact 4/10
Jan 29, 2026
Insider
Lee Eun Young sold 127 shares
10%+ Owner @ $1.36 ($172.09)
Latest Reports
BEARISH
424B5
6/10
Nexentis Technologies is offering 311,876 shares at $4.008/share (20% discount to $5.01 last sale), raising ~$1.25M befo
Jun 15, 2026
BEARISH
8-K
6/10
Nexentis Technologies Inc. entered into a securities purchase agreement to sell 311,876 shares of common stock in a regi
Jun 12, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jan 29, 2026 | Lee Eun | SELL | $172.09 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
1 unique insiders with 1 transactions. Net insider value: -$172.09 ($0.00 bought, $172.09 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 29, 2026 | Lee Eun Young | 10%+ Owner | SELL | 127 | $1.36 | $172.09 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BEARISH
424B5
6/10
Nexentis Technologies is offering 311,876 shares at $4.008/share (20% discount to $5.01 last sale),
Jun 15, 2026
BEARISH
8-K
6/10
Nexentis Technologies Inc. entered into a securities purchase agreement to sell 311,876 shares of co
Jun 12, 2026
NEUTRAL
8-K
4/10
Nexentis Technologies Inc. (NXTS) is executing a 1-for-7 reverse stock split, reducing the number of
Apr 6, 2026
BEARISH
8-K
5/10
Nexentis Technologies issued 600,000 unregistered shares to consultants for investor relations and b
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 17, 2026
other
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery compan
May 18, 2026
other
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
<p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a d
May 13, 2026
other
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
<p align="justify"><b>MITOLINE</b><sup><b>®</b></sup><b>-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre
May 5, 2026
other
Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™
<p align="justify">Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a
Mar 13, 2026
other
Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform
<p align="center"><i>Visit</i> <i>Nexentis</i> <i>at:</i> <a href="https://www.globenewswire.com/Tracker?data=nxN3Lga5OV8sgxFvuzwAIfwvQj56SWyl4wd_MUjO